Maria Helena Rigatto1, Tainá F Behle2, Diego R Falci3, Thiela Freitas3, Natane T Lopes4, Mariá Nunes4, Leonardo W Costa4, Alexandre P Zavascki5. 1. Infectious Diseases Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 2. Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, 2350 Ramiro Barcelos St., Porto Alegre 90.035-903, Brazil. 3. Infection Control Service, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil. 4. Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 5. Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, 2350 Ramiro Barcelos St., Porto Alegre 90.035-903, Brazil Department of Internal Medicine, Medical School, Universidade Federal do Rio Grande do Sul, Porto, Alegre, Brazil azavascki@hcpa.ufrgs.br.
Abstract
OBJECTIVES: The objectives of this study were to assess risk factors for acute kidney injury (AKI) in patients treated with polymyxin B, a last resort antibiotic against Gram-negative bacteria, with a focus on dose, and to determine the impact of AKI on mortality of these patients. METHODS: A multicentre prospective cohort study was performed including patients ≥18 years treated with intravenous polymyxin B for ≥48 h. The primary outcome was AKI defined by RIFLE criteria. Secondary outcomes were 30 day mortality and failure stage of AKI. Multivariate analysis with a Cox regression model was performed. The probability of developing AKI was determined in a logistic regression model. RESULTS: Four-hundred-and-ten patients were included. AKI occurred in 189 (46.1%) patients. Polymyxin B dose ≥150 mg/day was a risk factor for AKI: adjusted HR = 1.95, 95% CI = 1.31-2.89, P = 0.01. Higher weight and age were also independently associated with AKI. The probability of developing AKI significantly increased with doses between 150 and 199 mg/day, regardless of patient weight, with no significant increase with higher doses. Higher weight also increased the risk in patients receiving the same daily doses. AKI was barely associated with increased risk for 30 day mortality (adjusted HR = 1.35, 95% CI = 0.99-1.85, P = 0.06), while ≥150 mg/day did not increase this risk despite its association with AKI. CONCLUSIONS: Polymyxin B total dose is highly related to the risk of AKI, regardless of patient weight. Thirty-day mortality tended to be higher in patients who developed AKI. The relationship between dose, AKI and mortality must be further investigated in studies specifically designed to evaluate this latter outcome.
OBJECTIVES: The objectives of this study were to assess risk factors for acute kidney injury (AKI) in patients treated with polymyxin B, a last resort antibiotic against Gram-negative bacteria, with a focus on dose, and to determine the impact of AKI on mortality of these patients. METHODS: A multicentre prospective cohort study was performed including patients ≥18 years treated with intravenous polymyxin B for ≥48 h. The primary outcome was AKI defined by RIFLE criteria. Secondary outcomes were 30 day mortality and failure stage of AKI. Multivariate analysis with a Cox regression model was performed. The probability of developing AKI was determined in a logistic regression model. RESULTS: Four-hundred-and-ten patients were included. AKI occurred in 189 (46.1%) patients. Polymyxin B dose ≥150 mg/day was a risk factor for AKI: adjusted HR = 1.95, 95% CI = 1.31-2.89, P = 0.01. Higher weight and age were also independently associated with AKI. The probability of developing AKI significantly increased with doses between 150 and 199 mg/day, regardless of patient weight, with no significant increase with higher doses. Higher weight also increased the risk in patients receiving the same daily doses. AKI was barely associated with increased risk for 30 day mortality (adjusted HR = 1.35, 95% CI = 0.99-1.85, P = 0.06), while ≥150 mg/day did not increase this risk despite its association with AKI. CONCLUSIONS: Polymyxin B total dose is highly related to the risk of AKI, regardless of patient weight. Thirty-day mortality tended to be higher in patients who developed AKI. The relationship between dose, AKI and mortality must be further investigated in studies specifically designed to evaluate this latter outcome.
Authors: Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin Journal: Antimicrob Agents Chemother Date: 2015-08-31 Impact factor: 5.191
Authors: Christine J Kubin; Brian C Nelson; Cristina Miglis; Marc H Scheetz; Nathaniel J Rhodes; Sean N Avedissian; Serge Cremers; Michael T Yin Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Cristina Miglis; Nathaniel J Rhodes; Sean N Avedissian; Christine J Kubin; Michael T Yin; Brian C Nelson; Manjunath P Pai; Marc H Scheetz Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Nikolas J Onufrak; Gauri G Rao; Alan Forrest; Jason M Pogue; Marc H Scheetz; Roger L Nation; Jian Li; Keith S Kaye Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Adeola Okoduwa; Nabeela Ahmed; Yi Guo; Marco R Scipione; John Papadopoulos; Daniel P Eiras; Yanina Dubrovskaya Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191
Authors: Michael J Satlin; Nina Cohen; Kevin C Ma; Zivile Gedrimaite; Rosemary Soave; Gülce Askin; Liang Chen; Barry N Kreiswirth; Thomas J Walsh; Susan K Seo Journal: J Infect Date: 2016-07-09 Impact factor: 6.072
Authors: Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li Journal: ACS Infect Dis Date: 2015-09-04 Impact factor: 5.084